Companies: SGS, CMIC, INC.
SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
0% citation coverage1 regulatory sources
SGS has acquired CMIC, INC., a Chicago-based bioanalytical testing firm, expanding its North American capabilities. The move follows the Keystone Bioanalytical acquisition and signals SGS's commitment to end-to-end drug development lifecycle testing.
Executive Summary
- SGS bought CMIC, INC. on June 4, 2026, adding a Chicago bioanalytical lab to its North American footprint.
- This is SGS's second bioanalytical acquisition in two months, following the purchase of Keystone Bioanalytical on May 4, 2026.
- The expansion strengthens SGS's ability to offer integrated drug development lifecycle testing, covering early-phase through commercial support.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
SGS has acquired CMIC, INC., a Chicago-based bioanalytical testing firm, expanding its North American capabilities. The move follows the Keystone Bioanalytical acquisition and signals SGS's commitment to end-to-end drug development lifecycle testing. For pharma teams managing preclinical and clinical programs, the deal means broader access to LC-MS/MS expertise and a larger network of labs.
Key Takeaways
- SGS bought CMIC, INC. on June 4, 2026, adding a Chicago bioanalytical lab to its North American footprint.
- This is SGS's second bioanalytical acquisition in two months, following the purchase of Keystone Bioanalytical on May 4, 2026.
- The expansion strengthens SGS's ability to offer integrated drug development lifecycle testing, covering early-phase through commercial support.
What changed with the CMIC acquisition?
On June 4, 2026, SGS announced the acquisition of CMIC, INC., a Chicago-based provider of bioanalytical testing services [PRNewswire]. The deal includes laboratory facilities and specialized expertise in liquid chromatography-tandem mass spectrometry (LC-MS/MS) and other analytical techniques used to quantify drugs and metabolites in biological samples. Just one month earlier, on May 4, 2026, SGS acquired Keystone Bioanalytical, a Philadelphia-based firm also focused on LC-MS/MS-based bioanalysis [SGS]. Together, these moves represent a deliberate strategy to build out a North American bioanalytical network that can support pharma sponsors from early discovery through post-market surveillance.
SGS framed the CMIC acquisition as part of a broader push to offer end-to-end drug development lifecycle testing. The company has also introduced new specialized bioanalytical testing services in North America, including assays for oligonucleotides and gene therapies [SGS]. For pharma companies that rely on contract research organizations (CROs) for critical bioanalytical work, this consolidation creates a bigger, more geographically dispersed provider that can handle larger volumes and more complex modalities.
How does this affect pharma teams?
Clinical development and procurement teams evaluating CRO partners for upcoming programs should take note. SGS's expanded capacity in Chicago and Philadelphia means shorter sample shipping routes for many US-based sponsors, potentially improving turnaround times. The combined capabilities also allow SGS to offer a broader menu of validated assays, from small molecules to large biologics and novel modalities. For competitors — especially mid-sized specialty bioanalytical CROs — the pressure to differentiate on speed, technology, or niche expertise will intensify. Pharma companies may see more aggressive pricing or bundled service offerings as SGS integrates these labs and vies for market share against larger players like Labcorp and IQVIA. Teams should benchmark their current bioanalytical partners against SGS's new footprint when planning Phase I through III programs. The FDA's guidance on bioanalytical method validation, which requires rigorous documentation of assay performance, becomes easier to navigate when a CRO has deep experience across multiple analytical platforms [FDA].
Frequently Asked Questions
Why did SGS acquire CMIC, INC.?
SGS acquired CMIC to strengthen its North American bioanalytical testing capabilities, particularly in LC-MS/MS and other analytical methods used in drug development. The deal follows a similar acquisition of Keystone Bioanalytical a month earlier, signaling a strategic push to offer integrated, end-to-end lifecycle testing for pharma and biotech clients.
How does this affect drug developers?
Pharma companies now have access to a larger SGS laboratory network with more geographic coverage. This can lead to faster sample logistics, a wider array of validated assays, and stronger support for complex modalities like gene therapies and oligonucleotides. It may also shift the competitive dynamics among CROs, as SGS gains scale.
What types of testing does CMIC specialize in?
CMIC, INC. focuses on bioanalytical testing using LC-MS/MS, a core technique for quantifying drugs, metabolites, and biomarkers in biological matrices. These assays are essential for pharmacokinetic and toxicokinetic studies in preclinical and clinical development, and the FDA expects them to meet specific validation standards for use in regulatory submissions [FDA].
Related coverage
Stay Updated on Pharma News
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
